Minimizing efficacy differences between phase II and III RCTs

被引：0
|
作者：
Vibeke Strand
机构：
[1] Stanford University,Division of Immunology and Rheumatology
来源：
Nature Reviews Rheumatology | 2020年 / 16卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Results from phase II randomized controlled trials (RCTs) determine whether promising therapeutics will progress to phase III. According to detailed analyses in rheumatoid arthritis and psoriatic arthritis, phase II efficacy data systematically overestimate subsequent phase III results, raising the question of how this discrepancy might be addressed in future RCTs.
引用
收藏
页码：359 / 360
页数：1
相关论文
共 50 条
  • [1] Minimizing efficacy differences between phase II and III RCTs
    Strand, Vibeke
    [J]. NATURE REVIEWS RHEUMATOLOGY, 2020, 16 (07) : 359 - 360
  • [2] Efficacy gap between phase II and subsequent phase III studies in oncology
    Vreman, Rick A.
    Belitser, Svetlana, V
    Mota, Ana T. M.
    Hovels, Anke M.
    Goettsch, Wim G.
    Roes, Kit C. B.
    Leufkens, Hubert G. M.
    Mantel-Teeuwisse, Aukje K.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (07) : 1306 - 1313
  • [3] Balancing Phase II and III Efficacy Trials
    Bobby W. Sandage
    [J]. Drug information journal : DIJ / Drug Information Association, 1998, 32 (4): : 977 - 980
  • [4] Balancing Phase II and III efficacy trials
    Sandage, BW
    [J]. DRUG INFORMATION JOURNAL, 1998, 32 (04): : 977 - 980
  • [5] Comparison of results between the first and updated reports of phase III clinical trials (RCTs)
    Elimova, Elena
    Seruga, Bostjan
    Jiang, Haiyan
    Tannock, Ian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β3-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB)
    Rossanese, Marta
    Novara, Giacomo
    Challacombe, Ben
    Iannetti, Alessandro
    Dasgupta, Prokar
    Ficarra, Vincenzo
    [J]. BJU INTERNATIONAL, 2015, 115 (01) : 32 - 40
  • [7] Upper airway differences between Class II and Class III children
    Cao, Li
    [J]. AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS, 2017, 152 (04) : 442 - 442
  • [8] PHASE II INTO PHASE III
    Redman, Mary W.
    Goldman, Bryan
    Leblanc, Michael
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S92 - S92
  • [9] Model aims to reduce discrepancy between phase II, phase III trials
    Reynolds, T
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (19) : 1554 - 1556
  • [10] The disconnect between phase II and phase III trials of drugs for heart failure
    Muthiah Vaduganathan
    Stephen J. Greene
    Andrew P. Ambrosy
    Mihai Gheorghiade
    Javed Butler
    [J]. Nature Reviews Cardiology, 2013, 10 : 85 - 97
12345